Quick Evidence Summary
| Evidence type | Current status |
|---|---|
| Preclinical research | Rests largely on general GHRH-receptor pathway science, not CJC-1295-specific animal trials |
| Peer-reviewed human clinical trials | No dedicated large-scale trials of CJC-1295 itself identified |
| Anecdotal human reports | Widespread online and from manufacturer data, but uncontrolled and self-reported |
| Mechanistic plausibility | Strong in general terms, since GHRH-receptor agonism is well studied through Sermorelin |
| Regulatory status | Not FDA-approved; sold as a research chemical |
What CJC-1295 Is
CJC-1295 is a synthetic analog of growth-hormone-releasing hormone (GHRH). It exists in two forms. CJC-1295 with DAC (Drug Affinity Complex) binds to serum albumin in the blood, which extends its half-life to several days, meaning far less frequent dosing than the natural hormone would allow. CJC-1295 without DAC, more commonly called Mod GRF 1-29, has a short half-life of around 30 minutes and behaves closer to a standard GHRH fragment. Both versions are designed to act on the same receptor as endogenous GHRH.
Human Evidence
This is where CJC-1295 sits in an interesting middle ground, and it's worth being precise about it. Because CJC-1295 acts on the same GHRH receptor pathway that has been extensively studied through Sermorelin, a related and shorter GHRH fragment that was previously FDA-approved as the drug Geref, there is a large body of scientific understanding about how GHRH-receptor agonism works in humans generally. That's real, substantive science.
What's different is that CJC-1295 itself, as a distinct modified molecule, especially the DAC-extended version, has not been the subject of the same kind of dedicated, large-scale, peer-reviewed human clinical trials that Sermorelin went through on its way to approval. Much of what circulates about CJC-1295's specific effects and dosing in humans comes from smaller studies, manufacturer-reported data, and community-reported experience rather than large controlled trials specific to this exact molecule.
Why this matters: understanding how a receptor pathway behaves in general is not the same as having trial data on a specific modified molecule that acts on it. CJC-1295 benefits from borrowed plausibility through the Sermorelin research base, but it hasn't independently earned the same trial history, and that distinction shouldn't get blurred.
Preclinical (Animal) Evidence
The preclinical picture for CJC-1295 specifically is thinner than the human-pathway science might suggest. Most of the foundational animal and mechanistic work establishing how GHRH-receptor agonists stimulate growth hormone release comes from research on GHRH itself and on Sermorelin, rather than from dedicated CJC-1295 studies. CJC-1295's own preclinical data, where it exists, largely centers on confirming that the DAC modification behaves as intended, extending receptor engagement without fundamentally changing the mechanism.
Mechanistic Rationale
CJC-1295 binds the GHRH receptor, and this class of receptor interaction is mechanistically well understood in general terms. There is extensive basic science on GHRH physiology, how GHRH receptor activation triggers the pituitary to release growth hormone, and how that pathway is regulated. That general mechanism gives CJC-1295 a reasonable degree of biological plausibility even where the specific modified molecule has less dedicated trial data of its own. The DAC modification's purpose, extending half-life via albumin binding, is also mechanistically straightforward and doesn't itself change how the receptor interaction works.
Evidence Gaps and What Would Strengthen the Case
What's missing is specific to CJC-1295 as a molecule: dedicated, peer-reviewed, randomized controlled human trials rather than reliance on the broader GHRH-pathway science established through Sermorelin. Until CJC-1295 itself, and particularly the DAC-extended form most commonly used, goes through that kind of independent trial process, claims about its specific human effects should be understood as extrapolated from a shared receptor mechanism and from manufacturer or community-reported experience, not as independently confirmed clinical outcomes.
Regulatory Status
CJC-1295 is not an FDA-approved drug. It is currently sold as a research chemical for laboratory research use only. This is a meaningful distinction from Sermorelin, which did go through FDA approval as Geref. CJC-1295 has not inherited that approval history, and it should not be assumed to carry the same regulatory standing simply because it acts on a related pathway.
Bloodwork to Track
IGF-1 is the standard marker for tracking growth-hormone-axis activity, since growth hormone itself is difficult to measure reliably due to its pulsatile release. See the IGF-1 blood test explained for what the marker measures and how to interpret changes in it, and the peptide bloodwork guide for a broader baseline panel to consider alongside it.
Related Reading
For how CJC-1295 stacks up against another commonly paired peptide, see CJC-1295 vs Ipamorelin. For a direct look at the better-studied GHRH fragment referenced throughout this article, see Ipamorelin vs Sermorelin. BioStackIQ's Rate My Stack and Build Protocol can help you think through where a compound like this fits into a broader stack, with this evidence picture in mind.